The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Link
http://www.nature.com/articles/leu2010154.pdf
Reference12 articles.
1. Manning BD, Cantley LC . AKT/PKB signaling: navigating downstream. Cell 2007; 129: 1261–1274.
2. Zha H, Raffeld M, Charboneau L, Pittaluga S, Kwak LW, Petricoin III E et al. Similarities of prosurvival signals in Bcl-2-positive and Bcl-2-negative follicular lymphomas identified by reverse phase protein microarray. Lab Invest 2004; 84: 235–244.
3. Gulmann C, Espina V, Petricoin III E, Longo DL, Santi M, Knutsen T et al. Proteomic analysis of apoptotic pathways reveals prognostic factors in follicular lymphoma. Clin Cancer Res 2005; 11: 5847–5855.
4. Ackler S, Xiao Y, Mitten MJ, Foster K, Oleksijew A, Refici M et al. ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo. Mol Cancer Ther 2008; 7: 3265–3274.
5. Leseux L, Hamdi SM, Al Saati T, Capilla F, Recher C, Laurent G et al. Syk-dependent mTOR activation in follicular lymphoma cells. Blood 2006; 108: 4156–4162.
Cited by 57 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Unveiling the role of PIK3R1 in cancer: A comprehensive review of regulatory signaling and therapeutic implications;Seminars in Cancer Biology;2024-11
2. Importance of targeting various cell signaling pathways in solid cancers;International Review of Cell and Molecular Biology;2024
3. Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease;Signal Transduction and Targeted Therapy;2023-10-02
4. New pharmacotherapeutic approaches for the treatment of peripheral T-cell lymphoma;FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology;2023-05-16
5. Metabolic Biomarkers in B-Cell Lymphomas for Early Diagnosis and Prediction, as Well as Their Influence on Prognosis and Treatment;Diagnostics;2022-02-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3